It will closely work with existing and new business partners to expand its footprint.
It is scheduled to open in 2023 and will include a cutting-edge healthcare facility with a total of 126 beds.
The phase 3 trial is a multi-center, randomized, double-blind study of females with metastatic HER2-positive breast cancer.
This nasal spray is a generic version of Par Pharmaceutical, Inc.'s Nascobal Nasal Spray.
Palbociclib is used to treat a specific type of breast cancer.
The report added that the auditors also noticed raw materials being kept in extremely hot and humid circumstances.
The divestment agreement is expected to be completed by the end of July 2023.
The company voluntarily recalled all of its products from this site in August 2021.
This is the first approval for a generic version of Spiriva HandiHaler in the U.S.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
